ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VER Vernalis

6.17
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.17 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Vernalis Share Discussion Threads

Showing 3076 to 3100 of 3850 messages
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older
DateSubjectAuthorDiscuss
12/6/2015
09:43
Hi, you can see the headline broker recommendations history on a rival share price/info website that I won't mention but begins with M!Plus the updated recommendation yesterday was reported on a number of sites eg http://www.wkrb13.com/markets/632540/stifel-nicolaus-reaffirms-buy-rating-for-vernalis-plc-ver/
photon
12/6/2015
08:33
Thanks photon,can you post their article?
fhmktg
12/6/2015
05:51
Stifel upped their price target from 74p to 103p yesterday. They had previously been cautiously positive and upped targets in relatively small increments.
photon
11/6/2015
12:37
I'm somewhat surprised at the slow development of the cough formulations.
We are talking about relatively simple formulation of actives ( all well known) into delivery systems.
At the rate we are going it could take 5-7 years to get these into approval.
With NDA submission in spring/summer 2016 its going to be the cold and cough season of 2017 before #2 hits the market.
Am I missing something?

fhmktg
05/6/2015
15:52
Two degrees, if you are talking about the director buy, that was over a month ago, hence lower price.
battyliveson
05/6/2015
15:46
how does he managed to get them at an average of 59.9p when they were around 69p yesterday
twodegrees
05/6/2015
14:35
Still ticking up nicely. Got some for the Sipp as a long term hold as will be news driven. Has great potential and attractive to big pharma if US cold relief launches well.

Batty

battyliveson
02/6/2015
16:06
climbing again.
twodegrees
18/5/2015
17:46
Lots of buying at the close!
fhmktg
14/5/2015
16:07
Thanks for that twodegrees. I'll keep on topping up here I think.
investordave
14/5/2015
16:06
3. Full name of person(s) Woodford Investment
subject to the notification Management LLP (Woodford)
obligation:
---------------------------------- ---------------------------
4. Full name of shareholder(s) Clients of Woodford
(if different from 3.):
---------------------------------- ---------------------------
5. Date of the transaction 29 April 2015
and date on which the threshold
is crossed or reached:
---------------------------------- ---------------------------
6. Date on which issuer 30 April 2015
notified:
---------------------------------- ---------------------------
7. Threshold(s) that is/are
crossed or reached: 18%, 19%
---------------------------------- ---------------------------


8. Notified details:
--------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
--------------------------------------------------------------------------------------------------
Class/type Situation Resulting situation after
of previous the triggering transaction
shares to the triggering
transaction
if possible
using
the ISIN
CODE
--------------- ------------------------ -------------------------------------------------------
Number Number Number Number of % of voting
of of of voting rights
Shares Voting shares rights
Rights
--------------- ----------- ----------- ----------- ---------------------- ------------------
Direct Indirect Direct Indirect
--------------- ----------- ----------- ----------- ----------- --------- ------- ---------
Ordinary
1p Shares
GB00B3Y5L754 77,389,076 77,389,076 85,550,924 85,550,924 19.3%
--------------- ----------- ----------- ----------- ----------- --------- ------- ---------

twodegrees
14/5/2015
15:54
two degrees - Do you mean 20% of the company? If so, that's quite a statement of confidence.
investordave
14/5/2015
15:47
investordave, woodford keeps buying I think he has about 20% now
twodegrees
14/5/2015
15:29
Some sizeable trades going through, be interesting to see what they do when they get tipped ! Woodford been a holder for some time and keeps buying !
toffeeman4
14/5/2015
15:06
twodegrees - I didn't know that Woodford had bought Vernalis. What's your source for that please?
investordave
14/5/2015
14:41
I bought these in british biotech at £1.25 and never ever thought I might get anything back after they fell to the floor..but I suppose investments sometimes take time to materialise and this one is doing fine for me...small steps at a time and woodford on the case
twodegrees
14/5/2015
12:34
hvs - I agree. Something bubbling here.
investordave
14/5/2015
12:28
Just hang in there.

Feels a bid is coming soon.

Way undervalued.

hvs
13/5/2015
16:19
this just keep rising and yet it appears not to get so much publicity, more for us then.
twodegrees
06/5/2015
17:00
Always good when the directors put their money into shares!
fhmktg
01/5/2015
23:47
Fhmktg

I don't think British biotech original shareholders will get their stake money back for quite a while yet. Vernalis however is set to do very well.

barrie16
01/5/2015
12:06
Useful analysis by Motley Fool
fhmktg
01/5/2015
09:10
Nice one today.

This is going to EXPLODE.

hvs
01/5/2015
08:08
That's a good message for Mr W over his morning coffee!Well done Vernalis!
fhmktg
01/5/2015
07:49
Well done Vernalis

There is probably little clinical need (or rationale) for these TRIS products, but it certainly fulfils a commercial need and should be a big boost for the company and for shareholders.

They have approval in the US based on PK studies, the chances of getting approval in Europe on PK studies (without accompanying clinical trials in patients with coughs/colds) are close to zero

timbo003
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older

Your Recent History

Delayed Upgrade Clock